Involvement of VEGF and its receptors in ascites tumor formation

• Published in: Cancer chemotherapy and pharmacology 1999, Vol.43 (7), p.S72-S77
• Main Authors: SHIBUYA, M, LUO, J.-C, TOYODA, M, YAMAGUCHI, S
• Format: Article
• Language: English
• Subjects: Animal tumors. Experimental tumors; Animals; Antibodies - pharmacology; Ascites - metabolism; Ascitic Fluid - metabolism; Binding, Competitive; Biological and medical sciences; Capillary Permeability; Endothelial Growth Factors - biosynthesis; Endothelial Growth Factors - immunology; Endothelial Growth Factors - metabolism; Endothelium - pathology; Experimental digestive system and abdominal tumors; Guinea Pigs; Humans; Lymphokines - biosynthesis; Lymphokines - immunology; Lymphokines - metabolism; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred CBA; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - pathology; Radioligand Assay; Rats; Receptor Protein-Tyrosine Kinases - immunology; Receptor Protein-Tyrosine Kinases - metabolism; Receptors, Growth Factor - immunology; Receptors, Growth Factor - metabolism; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tumors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s002800051102

Vascular endothelial growth factor (VEGF) has potent endothelial cell mitotic and vascular permeability activity. Several reports have suggested that VEGF may be one of the major factors regulating ascites formation, although no quantitative and systematic analyses have been carried out. To determine the role of VEGF in ascites formation, we examined the expression of VEGF in 13 mouse ascites tumors (5 sarcomas, 3 carcinomas, and 5 hematopoietic malignancies). We found that significant amounts (6-850 ng/mL) of biologically active VEGF accumulated in the ascites fluid of all 13 tumors, particularly in tumors of sarcoma and carcinoma origin (430 +/- 234 ng/mL). The microvessel densities in the peritoneal walls of tumor-bearing mice, which are significantly higher than those in healthy mice, basically correlated with but did not parallel VEGF concentrations, suggesting the existence of an additional modulator(s) of the angiogenic process. Administration of anti-mouse VEGF-neutralizing antibody to mice bearing the carcinoma-derived ascites tumor MM2 suppressed ascites accumulation, tumor growth, and tendency to bleed. These results directly demonstrate the crucial role of VEGF in carcinoma-derived ascites tumor formation in vivo.